NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Interventional Procedures Advisory Committee

Minutes of the Committee’s 181st meeting held at 10:30 on Thursday 09th May 2019 at NICE, 10 Spring Gardens, London, SW1A 2BU

PRESENT:
Dr Tom Clutton-Brock (Chair)
Dr Wael Agur
Mr Jonathan Anderson
Dr Jonathan Bell
Mrs Sally Brearley
Dr Chris Carroll
Dr Andrew Cook (Vice Chair)
Mrs Suzanne Halliday
Mrs Rosemary Harris
Mr Colin Howie
Mr Tim Jackson
Dr Tim Kinnaird
Dr Neil McGuire
Miss Karen Nugent
Professor Frank Smith
Dr Dhiraj Tripathi (arrived at 10:52)

In Attendance
NICE Staff:

Kevin Harris – PD and Consultant Clinical Advisor, IPP
John Powell, Consultant Clinical Advisor, IPP
Lakshmi Mandava, Analyst, IPP
Helen Gallo, Senior Analyst, IPP
Xia Li, Analyst, IPP
Tika Ram – Analyst IPP
Rebecca Willans - Specialty Public Health Registrar
Deonee Stanislaus, Coordinator, IPP
Azad Hussain, Administrator, IPP
Ria Skelton, Senior Medical Editor, NICE
Helen Crosbie, PIP, NICE
Mrs Bijal Joshi, Programme Manager, IPP

Specialist Advisors:
Mr Barrie White – Specialist Advisor (IP1553)
Dr Katy Sinka – Specialist Advisor (IP1553)

Apologies:
Mr Mahmoud Elfar

Minutes of the IPAC meeting
Thursday 09th May 2019
Mr Anthony Hatswell
Mr Malcolm Lowe-Lauri
Mr Kieran Murphy
Dr Peter Murphy
Dr James Tysome

Note: The order in which the Committee took items of business at the meeting might differ from the agenda

Meeting started: 10:35

Introduction to the meeting

The Chairman welcomed the Committee Members. The Chairman also welcomed:
- Tika Ram; Technical Analyst in the Interventional Procedures Programme
- Barrie White; Specialist Advisor for IP1553 Patient safety and reduction of risk of transmission of Creutzfeldt–Jakob disease
- Katy Sinka; Specialist Advisor for IP1553 Patient safety and reduction of risk of transmission of Creutzfeldt–Jakob disease

The Chairman also welcomed the members of the public and company representatives present at the meeting.

Code of conduct for members of the public and company representatives attending the meeting

The Chairman outlined the code of conduct for the members of the public and company representatives attending the meeting.

1. Any Other Business

None

2. Minutes of previous meeting

Rosemary pointed out that in the previous minutes Kieran Murphy was inserted as present at the meeting where in fact Kieran was absent. This error will be corrected.

3. Matters arising

None

4. Agenda changes

The chairman informed the Committee that, the order of the agenda will be as follows IP1553, IP1019/2, IP1135, IP1723, IP1727.
5. **NICE’s Advisory Body guide to declaring a conflict of interest**

The Chairman drew the Committee’s attention to NICE’s advisory body quick guide for declaring conflicts of interest.

6. **Newly Notified Procedures**

*IP1553 Patient safety and reduction of risk of transmission of Creutzfeldt–Jakob disease*

The discussion on IP1553 Patient safety and reduction of risk of transmission of Creutzfeldt–Jakob disease started at 10:46

No conflicts of interest were declared for this procedure

The Committee was reminded that equalities issues was discussed at the brief stage.

Introduced by Tom Clutton-Brock and Katy Sinka and Barrie White

The Chairman declared a Part Two and members of the public as well as left the meeting at 11:26

The Committee made its provisional recommendations on the safety and efficacy of the procedure.

The discussion on IP1553 Patient safety and reduction of risk of transmission of Creutzfeldt–Jakob disease ended at 13:35.

The members of the public as well as company representatives returned at 14:00

*IP1019/2 Irreversible electroporation for treating primary liver cancer*

The discussion on IP1019/2 Irreversible electroporation for treating primary liver cancer started at 14:02

Company representatives from AngioDynamics were present for this topic.

No conflicts of interest were declared for this procedure

The Committee was reminded that equalities issues was discussed at the brief stage.

Introduced by Tim Kinnaird and John Bell

The Chairman declared a Part Two and members of the public as well as company representatives left the meeting at 14:28
The Committee made its provisional recommendations on the safety and efficacy of the procedure.

The discussion on IP1019/2 Irreversible electroporation for treating primary liver cancer ended at 14:59

The company representatives returned at 15:01

IP1135 Midcarpal hemiarthroplasty for wrist arthritis
The discussion on IP1135 Midcarpal hemiarthroplasty for wrist arthritis started at 15:02

Company representatives from Lavender Medical Ltd. were present for this topic.

No conflicts of interest were declared for this procedure

The Committee was reminded that equalities issues was discussed at the brief stage.

Introduced by Karen Nugent and Colin Howie

The Chairman declared a Part Two and company representatives left the meeting at 15:16

The Committee made its provisional recommendations on the safety and efficacy of the procedure.

The discussion on IP1135 Midcarpal hemiarthroplasty for wrist arthritis ended at 15:22

The company representatives returned at 15:23

7. Public Consultation comments

IP1723 Transurethral laser ablation for recurrent non-muscle invasive bladder cancer

The discussion on IP1723 Transurethral laser ablation for recurrent non-muscle invasive bladder cancer started at 15:23

Company representatives from Promed were present for this topic.

No conflicts of interest were declared for this procedure

The Committee was reminded that equalities issues was discussed at the brief stage.

Introduced by Tom Clutton-Brock

The Committee considered the consultation comments
The Chairman declared a Part Two and company representatives left the meeting at 15:29

The Committee upheld its decision on the safety and efficacy of the procedure.

The discussion on IP1723 Transurethral laser ablation for recurrent non-muscle invasive bladder cancer ended at 15:32

No members of public or company present from this point onwards.

IP1727 Ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

The discussion on IP1727 Ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids started at 15:33

No conflicts of interest were declared for this procedure

The Committee was reminded that equalities issues was discussed at the brief stage.

Introduced by Wael Agur

The Committee considered the consultation comments

The Committee upheld its decision on the safety and efficacy of the procedure.

The discussion on IP1727 Ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids ended at 15:40

9. **Other meeting matters**

None

10. **Date of the next meeting**

The 182nd meeting of the Interventional Procedures Advisory Committee will be held on Thursday 13th June 2019 and will start promptly at 10:30. The meeting will be held at NICE, 10 Spring Gardens, London, SW1A 2BU

The meeting ended at 15:40